|
Match
|
Document |
Document Title |
|
|
DE102018010063A1 |
Preparation of Vesicular Phospholipid Gels by Screw Extrusion
The present invention relates to a process for the preparation of vesicular phospholipid gels (VPG) prepared by means of screw extrusion. In particular, the invention relates to a method for... |
|
|
DE10262193B4 |
Cosmetic use of an active substance for stimulating type 2 and / or type 3 human beta-defensins, use of such an active substance for the preparation of a pharmaceutical composition containing such an active substance and use of such an active substance in the field of tissue reconstruction
Cosmetic use of an active ingredient selected from the group consisting of a Boldo extract, a cocoa extract and jasmonic acid, wherein the extract is obtained by aqueous extraction or extraction... |
|
|
DE102012108560B4 |
Noncovalent self-assembling hydrogel matrix for biotechnological applications
A noncovalent self-assembling hydrogel matrix for biotechnological applications containing a covalent polymer-peptide conjugate, the covalent polymer-peptide conjugate comprising conjugates of two... |
|
|
DE212017000061U1 |
Composition for detecting a single-stranded target RNA
A composition for detecting a single-stranded target RNA in an acellular sample comprising a plurality of RNAs, comprising: (i) a C2c2-guideRNA that hybridizes to the single-stranded target RNA;... |
|
|
DE212017000062U1 |
Use for detecting a single-stranded target RNA
Use of: (i) a C2c2-guideRNA that hybridizes to a single-stranded target RNA; (ii) a labeled detection RNA; and (iii) a C2c2 protein, splits the RNA present in a sample, wherein the C2c2 protein... |
|
|
DE212017000056U1 |
Kits for detecting a target RNA in a sample
A kit for detecting a target RNA in a sample comprising a plurality of RNAs, the kit comprising: (a) a labeled detection RNA; and (b) a C2c2 protein and / or a nucleic acid encoding the C2c2... |
|
|
DE102017107661A1 |
SH2B adapter protein-3 for the prediction of a bone marrow response and immune response
The present invention relates to the SH2B adapter protein-3 (SH2B3) for use as a diagnostic marker. Furthermore, the present invention relates to a method for determining the expression of the... |
|
|
DE102007004991B4 |
Use of RiV preparations for the treatment of cerebral infarction
Use of BK-RiV preparations containing RiV particles with a size of 30 to 70 nm for the preparation of medicaments for the treatment of cerebral infarction, wherein the preparation of BK-RiV... |
|
|
DE202018100276U1 |
Halipray suitable for filling with stem cell active peptide active ingredients
A throat spray, at least comprising a compact having a latching sleeve with a hollow structure, wherein an elongated nozzle protruding from the compact is provided laterally at the upper portion... |
|
|
DE202018100274U1 |
Nasal spray suitable for filling with stem cell active peptide active ingredients
A nasal spray, at least comprising a compact, wherein a nozzle is provided at the upper portion of the compact and a latching sleeve having a hollow structure is provided at the lower portion of... |
|
|
DE112015004182T5 |
An antifungal composition comprising antimycotic peptide and terpene alcohol
A composition having enhanced antifungal activity comprising peptides such as a protamine hydrolyzate and which is suitable for low cost industrial use can be provided by using a combination of a... |
|
|
DE102016205950A1 |
Means for use in inflammatory conditions of the mucous membranes
The present invention relates to an agent which comprises anion exchange moieties suitable for adsorbing bacterial lipopolysaccharides (LPS) and / or lipo - hexonic acids (LTA), for use in the... |
|
|
DE112015005320T5 |
Janus nanoparticles and methods for making the same
The present invention is to provide a Janus nanoparticle, with a simple method, a drug may be encapsulated in, and a method of manufacturing the same. According to the present invention, a method... |
|
|
DE112004002217B4 |
Protein-forming complex with a c-Jun protein, nucleic acid encoding the same, and methods using the same
Use of a protein of the following (a) or (b): (a) a protein comprising any of the amino acid sequences of SEQ ID NOS: 95 to 99, SEQ ID NOS: 1 to 69, SEQ ID NOS: 70 to 87, SEQ ID NOS: SEQ ID NOS:... |
|
|
DE19616486C5 |
A method for lowering blood glucose levels in mammals
Oral use of inhibitors of dipeptidyl peptidase (DP IV) enzymatic activity without additional administration of exogenous insulinotropic peptides GIP1-42, GLP-17-36 or analogs thereof, for lowering... |
|
|
DE102010033458B4 |
Emulsified Lektinzusammensetzungen and their use
Lektinzusammensetzung for the prophylaxis and / or treatment of aromatase inhibitor-, antiestrogen or estrogen receptor modulator (SERM) - or / and GnRH analogues-related adverse side effects in a... |
|
|
DE102010033575B4 |
ASPP2 splice variant
Method for the in vitro determination of the presence or a predisposition of a patient for the development of cancer, characterized in that in a biological sample from the patient the presence of... |
|
|
DE102014101663A1 |
Synthetic artificial peptides with antimicrobial activity
The present invention relates to antimicrobial peptides of the general formula AxByCz with x, z ≥ 1, y ≥ 3, and x + y + z ≤ 50, where A and C are each independently have at least 65% basic amino... |
|
|
DE69831673C5 |
USE OF EXEDINEN AND THEIR ANTAGONISTS TO REDUCE THE food intake
Use of an exendin or an exendin agonist selected from exendin-3, exendin-4, exendin-4 (1-30), Exendin-4- (1-30) amide, exendin-4 (1-28) - amide, 14Leu, 25Phe exendin-4 amide, 14Leu, 25Phe... |
|
|
DE10066235C5 |
Method and medicament for the inhibition of expression of a given gene
A method for inhibiting the expression of a given target gene in a mammalian cell, wherein a vector for coding at least one consisting of 15 to 2 base pairs oligoribonucleotide with... |
|
|
DE102010039019B4 |
Antibodies against 6-sulfo LacNAc positive human dendritic cells and their use
Composition comprising a) at least one anti-SLAN antibody which specifically binds to human dendritic cells, the surface of the P selectin glycoprotein ligand 1 (PSGL-1) with the O-linked glycan... |
|
|
DE50005985C9 |
METHOD FOR PRODUCING IL-1RA, A THERAPEUTIC ACTIVE PROTEIN FROM BODY FLUIDS
A process for the manufacture of IL-1Ra in a syringe for use as a medicament, the syringe filled with blood of an organism, incubated and thereby IL-1Ra is formed in the blood with the proviso... |
|
|
DE19756864C5 |
Neural progenitor cells, methods for their preparation and their use for the therapy of neural defects
Isolated, purified precursor cells with neuronal or glial properties from embryonic stem cells, containing at most about 15% primitive embryonic and non-neutral cells obtainable by the following... |
|
|
DE102010025935B4 |
collagen
From an individual of the species Rhopilema derived collagen with a ratio of proline to hydroxyproline of at least 1.9: 1 and a glycosylation measured by the ratio of Dissacchariden to... |
|
|
DE112012002928T5 |
Application method of activated functional proteins to improve animal health
It has been found that feeding a composition which includes an activated growth factor or activated growth factors, the feed / gain ratio increases, increases the overall weight gain, the required... |
|
|
DE50005985C5 |
METHOD FOR PRODUCING IL-1RA, A THERAPEUTIC ACTIVE PROTEIN FROM BODY FLUIDS
A process for the manufacture of IL-1Ra in a syringe for use as a medicament, the syringe filled with blood of an organism, incubated and thereby IL-1Ra is formed in the blood with the proviso... |
|
|
DE102004043153B4 |
Invention relating to GLP-1 and exendin
The present invention relates to peptide derivatives of GLP-1, exendin-3 and exendin-4 as well as a process for preparing a pharmaceutical agent for the presentation and treatment of... |
|
|
DE102012203547A1 |
Antimicrobial peptides
The present invention relates to a new antimicrobial peptide, which comprises at least eight consecutive amino acids, wherein the peptide has a sequence having the following formula:... |
|
|
DE102012003286A1 |
Combination of lipid transfer proteins and phenol derivatives containing plant compounds with locally-mucosal efficiency
The present invention relates to combinations, in particular for local mucosal application, especially in solid, semisolid or liquid preparation containing lipid transfer proteins from plants,... |
|
|
DE102012008730A1 |
Oral composition, useful e.g. as dietary supplement, comprises monounsaturated fatty acids comprising oleic acid e.g. oleic acid-((Z)-9-octadecenoic acid) in combination with peptides consisting of specific amino acids and/or antioxidant
Oral composition comprises monounsaturated 18C-fatty acids comprising oleic acid and/or oleic acid derivatized by hydroxy, amino or nitro group, preferably oleic acid-((Z)-9-octadecenoic acid),... |
|
|
DE102011117839A1 |
Preparation of hydrogels by Diels-Alder reaction
Hydrogel, prepared by covalently crosslinking macromonomers by Diels-Alder [4 + 2] cycloaddition. |
|
|
DE4420157B4 |
New growth / differentiation factor of the TGF-β family
Use of a pharmaceutical composition comprising a protein which is encoded by a DNA sequence which (A) nucleotides 1783 to 2142, 640-2142 or 1837-2142 of SEQ ID NO: 1, (B) one of the sequences from... |
|
|
DE102004004043B4 |
Purification of high molecular compounds by means of affinity membrane chromatography
Process for the purification and / or isolation of data contained in a solution or suspension of high molecular weight compounds with the capability of metal chelate formation, comprising the... |
|
|
DE102010039018B4 |
Anti-La antibodies and their use for Immunotargeting
A recombinant antibody comprising a.) a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La, binds, and b.) a binding moiety - An... |
|
|
DE102011017208A1 |
Bivalirudin and other hirudin analogs for preservation of cellular functionality in clinical cell therapy
The present invention relates to pharmaceutical compositions for cell therapy suitable for stem cell therapy non-embryonic stem cells and the only coagulation inhibiting component at least one... |
|
|
DE102010052941A1 |
Therapeutic protein
The present invention relates to the use of the protein Gremlin, and a fusion protein comprising a) a first poly-peptide having an immunoglobulin Fc domain, as well as b), comprises a second... |
|
|
DE102008062136B4 |
Pharmaceutical composition based on peptide from camel milk
Use of a peptide comprising one of the sequences SEQ ID NO. 1 (Lactophorin A), SEQ ID NO. 2 (Lactophorin B) or SEQ ID no. 7 having, for the treatment of a disease treatable by inhibition of human... |
|
|
DE102010042359A1 |
Marker sequences for multiple sclerosis and their use
The present invention relates to novel marker sequences for multiple sclerosis and its diagnostic use, including a method for screening potential drugs for multiple sclerosis - diseases using... |
|
|
DE19735587B4 |
Peptide having radioprotective effect, this containing cosmetic or pharmaceutical composition for nucleic acid encoding, manufacturing processes for this peptide and use as radioprotektives agent
Peptide having radioprotective effect, the sequence of SEQ ID No .: 2: Cys Ala Leu Val Tyr Pro Ala Gln Cys, or the sequence SEQ ID NO. 3:Ala Leu Ser Tyr Pro Ala Gln having. |
|
|
DE102010037469A1 |
Process for reducing the endotoxin content in a collagen-containing material
The present invention relates to a process for reducing the endotoxin content in a collagen containing material comprising the steps of: - Treating the collagen-containing material with liquor; -... |
|
|
DE102010040153A1 |
Fabric combination for the treatment of inflammatory or infectious diseases
The present invention relates to a material combination comprising a) at least one activatable by a reducing substance antimicrobial peptide, and b) at least one reducing agent for the treatment... |
|
|
DE102010036261A1 |
New peptide having a length of two to five monomers, where the monomers are an alpha hydroxy-4(1H)-pyridinone compounds, useful to treat metal (preferably iron, copper or aluminum) storage disorders, preferably siderosis
Peptide having a length of two to five monomers, where at least one of the monomers is an alpha -hydroxy-4(1H)-pyridinone compounds (I), is new. Peptide having a length of two to five monomers,... |
|
|
DE102010039019A1 |
Antibodies against 6-sulfo LacNAc positive human dendritic cells and their use
The invention relates to a composition containing at least one anti-SLAN antibody. Furthermore, the invention relates to the diagnostic and therapeutic use of this composition. The object of the... |
|
|
DE102010039018A1 |
Anti-La antibodies and their use for Immunotargeting
The invention relates to antibodies against the human La protein and their application for Immunotargeting, in particular of tumor cells. The object of the invention is the provision of improved... |
|
|
DE102010039015A1 |
Linker peptide and its use in fusion proteins
The invention relates to linker peptides, fusion proteins and fusion protein complexes containing them, processes for the production of fusion proteins and their use. The object of the invention... |
|
|
DE102010033458A1 |
Use of lectin composition for e.g. prophylaxis and/or treatment of gonadotropin releasing hormone-analogues-related adverse drug side effects, comprising emulsified lectin, and optionally further auxiliary substances and carrier substances
Use of a lectin composition is claimed for e.g. prophylaxis and/or treatment of aromatase inhibitors, antiestrogen or estrogen receptor modulator (SERM) and/or gonadotropin releasing... |
|
|
DE102010033575A1 |
ASPP2 splice variant
Disclosed is a method for the in vitro determination of the presence or a predisposition of a patient for the development of cancer, in a biological sample from the patient the presence of a... |
|
|
DE102010032482A1 |
New receptor agonist having renin-suppressing activity, antihypertrophic activity and influence of second messenger cyclic guanosine monophosphate during vasodilation, natriuresis and diuresis, useful to treat e.g. nephrotic syndrome
Receptor agonist having renin-suppressing activity, antihypertrophic (antifibrotic) activity and influence of second messenger cyclic guanosine monophosphate (cGMP) during vasodilation,... |
|
|
DE102010025935A1 |
Collagen with specified proline to hydroxyproline ratio and glycosylation degree as measured by the ratio of disaccharides to monosaccharides, useful as wound gel for treating wounds, and for tissue engineering
Collagen with a ratio of proline to hydroxyproline of at least 1.9:1 and a glycosylation degree as measured by the ratio of disaccharides to monosaccharides of at least 75:1, is claimed. An... |
|
|
DE102010032149A1 |
Nano-hydrogels for the therapeutic and non-therapeutic treatment, in particular for the therapy of states of stress and regeneration of damaged cell systems (Nano-shuttle system)
The object of the invention is to provide a composition which is suitable as a particularly effective drug supplier or carrier for the therapeutic and non-therapeutic treatment. This object is... |